• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.头孢哌酮-舒巴坦组合的体外抗菌谱、协同作用的发生情况以及稀释药敏试验浓度的建议。
J Clin Microbiol. 1987 Sep;25(9):1725-9. doi: 10.1128/jcm.25.9.1725-1729.1987.
2
[In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].舒巴坦与亚胺培南、美罗培南和头孢哌酮联合对耐碳青霉烯类鲍曼不动杆菌分离株的体外协同活性
Mikrobiyol Bul. 2014 Apr;48(2):311-5. doi: 10.5578/mb.7104.
3
In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.头孢哌酮和舒巴坦单独及联合应用对耐头孢哌酮肠杆菌科细菌和非发酵菌的体外活性。
Antimicrob Agents Chemother. 1990 Nov;34(11):2256-9. doi: 10.1128/AAC.34.11.2256.
4
Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.头孢哌酮-舒巴坦组合的药敏试验标准及质量控制指南。
J Clin Microbiol. 1988 Jan;26(1):13-7. doi: 10.1128/jcm.26.1.13-17.1988.
5
[Effects of sulbactam on the activity of cefoperazone against various clinical isolates].舒巴坦对头孢哌酮针对各种临床分离株活性的影响
Jpn J Antibiot. 1989 Apr;42(4):896-909.
6
In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.头孢哌酮-舒巴坦组合对554株临床分离菌株的体外抗菌活性,包括综述及β-内酰胺酶研究
Diagn Microbiol Infect Dis. 1985 Nov;3(6):489-99. doi: 10.1016/s0732-8893(85)80005-5.
7
The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.头孢哌酮-舒巴坦联合制剂。体外特性,包括β-内酰胺酶稳定性、抗菌活性以及纸片扩散法检测的解释标准。
Am J Clin Pathol. 1985 Oct;84(4):496-504. doi: 10.1093/ajcp/84.4.496.
8
Comparative in vitro activity of cefoperazone and various combinations of cefoperazone/sulbactam.头孢哌酮与头孢哌酮/舒巴坦不同组合的体外活性比较
Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):45-9. doi: 10.1016/0732-8893(90)90053-x.
9
[Synergy between sulbactam and ampicillin or cefoperazone in antimicrobial activity against beta-lactamase producing microorganisms. Results with the use of microdilution broth method].[舒巴坦与氨苄西林或头孢哌酮对产β-内酰胺酶微生物抗菌活性的协同作用。采用微量稀释肉汤法的结果]
Jpn J Antibiot. 1990 Jul;43(7):1214-24.
10
Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.使用预测性检测板开发用于头孢哌酮-舒巴坦扩散试验的新型试纸条。
Antimicrob Agents Chemother. 1992 Feb;36(2):394-400. doi: 10.1128/AAC.36.2.394.

引用本文的文献

1
Performance evaluation of four antibiotics using the BD Phoenix™ NMIC-413 antimicrobial susceptibility testing panel for carbapenem-resistant and carbapenem-resistant .使用BD Phoenix™ NMIC - 413抗菌药物敏感性检测板对耐碳青霉烯类和耐碳青霉烯类进行四种抗生素的性能评估。 (注:原文中“carbapenem-resistant and carbapenem-resistant”表述重复,疑似有误,但按要求进行了翻译)
Front Microbiol. 2025 Jul 4;16:1593674. doi: 10.3389/fmicb.2025.1593674. eCollection 2025.
2
Molecular and epidemiological characterization of carbapenem-resistant hypervirulent in Huaian, China (2022-2024): a retrospective study.中国淮安耐碳青霉烯类高毒力菌株的分子与流行病学特征(2022 - 2024年):一项回顾性研究
Front Cell Infect Microbiol. 2025 Jun 4;15:1569004. doi: 10.3389/fcimb.2025.1569004. eCollection 2025.
3
Molecular characteristics and antibiotic resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa in Nanning, China.中国南宁地区多重耐药铜绿假单胞菌的分子特征及耐药机制。
BMC Microbiol. 2024 Nov 15;24(1):478. doi: 10.1186/s12866-024-03640-7.
4
Predictors of Mortality, Drug Resistance, and Determinants among Carbapenem-Resistant Infections in Chinese Elderly Patients.中国老年患者碳青霉烯类耐药感染的死亡率、耐药性及决定因素的预测指标
Can J Infect Dis Med Microbiol. 2024 Aug 28;2024:5459549. doi: 10.1155/2024/5459549. eCollection 2024.
5
Antibiotic resistance and epidemiological characteristics of polymyxin-resistant .耐多药鲍曼不动杆菌的抗生素耐药性及流行病学特征。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 May 28;49(5):737-747. doi: 10.11817/j.issn.1672-7347.2024.230567.
6
Clinical characteristics and antimicrobial therapy of healthcare-associated carbapenem-non-susceptible gram-negative bacterial meningitis: a 16-year retrospective cohort study.医疗机构相关性碳青霉烯类药物不敏感革兰氏阴性菌脑膜炎的临床特征和抗菌治疗:一项 16 年回顾性队列研究。
BMC Infect Dis. 2024 Apr 2;24(1):368. doi: 10.1186/s12879-024-09237-9.
7
Epidemiological, Genetic, and Phenotypic Characteristics of Non-Typhoidal in Young Children, as Obtained from a Tertiary Hospital in Guangzhou, China.从中国广州一家三级医院获取的幼儿非伤寒性[具体疾病未明确]的流行病学、遗传学和表型特征
Microorganisms. 2023 Sep 28;11(10):2433. doi: 10.3390/microorganisms11102433.
8
Assessment of Effective Antimicrobial Regimens and Mortality-Related Risk Factors for Bloodstream Infections Caused by Carbapenem-Resistant .耐碳青霉烯类药物所致血流感染的有效抗菌方案及死亡率相关危险因素评估
Infect Drug Resist. 2023 May 1;16:2589-2600. doi: 10.2147/IDR.S408927. eCollection 2023.
9
Comparison of the Distribution and Changes in the Antibiotic Resistance of Clinical Bacterial Isolates from the Lower Respiratory Tract of Children in Shenzhen Before the Epidemic, During the Epidemic, and During the Period of Normalized Prevention and Control of COVID-19.深圳儿童下呼吸道临床分离菌在新冠疫情前、疫情期间及常态化防控期间的抗生素耐药性分布及变化比较
Infect Dis Ther. 2023 Feb;12(2):563-575. doi: 10.1007/s40121-022-00751-4. Epub 2023 Jan 4.
10
Emergence of Hypervirulent ST11-K64 Poses a Serious Clinical Threat in Older Patients.ST11-K64 高毒力株的出现对老年患者构成严重临床威胁。
Front Public Health. 2022 Mar 4;10:765624. doi: 10.3389/fpubh.2022.765624. eCollection 2022.

本文引用的文献

1
Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins.阿米卡星联合用药对中度敏感于第三代头孢菌素的肠杆菌科细菌的抗菌活性。
Antimicrob Agents Chemother. 1982 Dec;22(6):985-9. doi: 10.1128/AAC.22.6.985.
2
Principal beta-lactamases responsible for resistance to beta-lactam antibiotics in urinary tract infections.导致尿路感染对β-内酰胺类抗生素耐药的主要β-内酰胺酶。
Antimicrob Agents Chemother. 1980 Jun;17(6):929-36. doi: 10.1128/AAC.17.6.929.
3
Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.头孢哌酮:对其体外抗菌活性、药理特性及治疗效果的综述。
Drugs. 1981 Dec;22(6):423-60. doi: 10.2165/00003495-198122060-00002.
4
Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.头孢哌酮与两种β-内酰胺酶抑制剂舒巴坦和克拉维酸对拟杆菌属的活性与β-内酰胺酶的产生相关。
Antimicrob Agents Chemother. 1982 Sep;22(3):398-405. doi: 10.1128/AAC.22.3.398.
5
Bactericidal activity of cefoperazone with CP-45,899 against large inocula of beta-lactamase-producing Haemophilus influenzae.头孢哌酮与CP-45,899对产β-内酰胺酶的流感嗜血杆菌大量接种物的杀菌活性。
Antimicrob Agents Chemother. 1981 Jul;20(1):63-5. doi: 10.1128/AAC.20.1.63.
6
Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.头孢哌酮与β-内酰胺酶抑制剂联合应用的协同活性。
J Antimicrob Chemother. 1981 Mar;7(3):287-92. doi: 10.1093/jac/7.3.287.
7
Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.β-内酰胺酶抑制剂YTR 830、克拉维酸钠和舒巴坦与阿莫西林或氨苄西林联合使用的比较活性。
Antimicrob Agents Chemother. 1984 Oct;26(4):580-2. doi: 10.1128/AAC.26.4.580.
8
In vitro activity and disk susceptibility of Timentin: current status.替卡西林/克拉维酸的体外活性及纸片药敏:现状
Am J Med. 1985 Nov 29;79(5B):25-32. doi: 10.1016/0002-9343(85)90125-1.
9
Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum.头孢匹罗(HR 810)的β-内酰胺酶稳定性,一种具有广谱抗菌活性的新型头孢菌素。
Antimicrob Agents Chemother. 1986 Nov;30(5):713-8. doi: 10.1128/AAC.30.5.713.
10
Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.β-内酰胺酶抑制剂YTR 830、克拉维酸和舒巴坦与β-内酰胺联合应用对产β-内酰胺酶厌氧菌的比较活性
Antimicrob Agents Chemother. 1986 Nov;30(5):789-91. doi: 10.1128/AAC.30.5.789.

头孢哌酮-舒巴坦组合的体外抗菌谱、协同作用的发生情况以及稀释药敏试验浓度的建议。

In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.

作者信息

Jones R N, Barry A L, Packer R R, Gregory W W, Thornsberry C

机构信息

Clinical Microbiology Institute, Tualatin, Oregon 97062.

出版信息

J Clin Microbiol. 1987 Sep;25(9):1725-9. doi: 10.1128/jcm.25.9.1725-1729.1987.

DOI:10.1128/jcm.25.9.1725-1729.1987
PMID:3498740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC269316/
Abstract

Broth microdilution tests and an antimicrobial interaction (synergy) studies using various combinations of cefoperazone and sulbactam were performed in an effort to determine the most appropriate in vitro dilution test system. The test results with cefoperazone and sulbactam were categorized as synergistic (complete or partial) for nearly 80% of the strains isolated from clinical trial patients. The results indicate that the cefoperazone-sulbactam fixed ratio (2:1) maximized the cefoperazone spectrum of activity and best approximated the parenteral formulation of the drug. The cefoperazone-sulbactam combination had a greater antimicrobial activity than did the other comparison beta-lactams, except for imipenem, tested against strains of the family Enterobacteriaceae. To be consistent with the National Committee for Clinical Laboratory Standards interpretive breakpoints for cefoperazone alone, the following MIC breakpoints should be applied to the combination (2:1 ratio): less than or equal to 16/8 micrograms/ml, susceptible; 32/16 micrograms/ml, moderately susceptible; and greater than or equal to 64/32 micrograms/ml, resistant.

摘要

进行了肉汤微量稀释试验以及使用头孢哌酮和舒巴坦的各种组合进行的抗菌相互作用(协同作用)研究,以确定最合适的体外稀释试验系统。从临床试验患者中分离出的近80%的菌株,头孢哌酮和舒巴坦的试验结果被归类为协同(完全或部分)。结果表明,头孢哌酮-舒巴坦固定比例(2:1)使头孢哌酮的活性谱最大化,并且最接近该药物的肠胃外制剂。除亚胺培南外,头孢哌酮-舒巴坦组合对肠杆菌科菌株的抗菌活性高于其他比较性β-内酰胺类药物。为与美国国家临床实验室标准委员会单独针对头孢哌酮的解释性折点保持一致,以下MIC折点应适用于该组合(2:1比例):小于或等于16/8微克/毫升,敏感;32/16微克/毫升,中度敏感;大于或等于64/32微克/毫升,耐药。